Welcome to our dedicated page for AKTIS ONCOLOGY news (Ticker: AKTS), a resource for investors and traders seeking the latest updates and insights on AKTIS ONCOLOGY stock.
Aktis Oncology, Inc. (Nasdaq: AKTS) is a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors, and its news flow reflects this specialization. Company announcements emphasize progress in its miniprotein radioconjugate platform, which is designed to deliver radioisotopes selectively to tumors while limiting exposure to normal tissues.
News related to Aktis Oncology includes capital markets milestones, such as the closing of its upsized initial public offering and the start of trading on the Nasdaq Global Select Market under the AKTS ticker. These updates provide context on how the company is financing its research and development activities in targeted alpha radiopharmaceuticals.
Investors and observers can also expect coverage of pipeline developments. Aktis Oncology has highlighted programs such as AKY-1189 and AKY-2519, as well as its most advanced program targeting Nectin-4 with a miniprotein radioconjugate that it describes as having multi-indication potential across multiple tumor types. News may discuss clinical progress, platform refinements, and efforts to expand the reach of its radiopharmaceutical candidates to larger patient populations.
Another recurring theme in Aktis Oncology news is its strategic collaboration with Eli Lilly and Company, which is intended to apply the company’s miniprotein platform to novel radioconjugates outside its proprietary pipeline. Updates may reference how this collaboration fits into the company’s broader strategy.
For readers following AKTS, the news page offers a way to track developments in its clinical programs, financing events, and partnership activities over time. Regularly reviewing this coverage can help provide a clearer picture of how the company’s radiopharmaceutical platform and solid tumor pipeline are evolving.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Akoustis Technologies (NASDAQ: AKTS) announced a significant milestone with its first volume purchase order for Wi-Fi 6E filters, marking a new partnership with a leading U.S. service provider. These filters will enhance high-speed connectivity in cable gateway products utilizing the advanced XBAW® technology. The initial deployment includes two filter solutions operating at 5.6 GHz and 6.6 GHz, supporting expanded spectrum capacity in the UNII 1-4 and UNII 5-8 bands. The company is ramping up production capacity to 0.5 billion filters annually at its New York facility, driven by strong demand across Wi-Fi and 5G product lines. CEO Jeff Shealy emphasized the importance of this relationship in advancing cutting-edge Wi-Fi technology. Akoustis has secured over 20 design wins and is actively expanding its customer base in the rapidly growing RF filter market.
Akoustis Technologies, Inc. (NASDAQ: AKTS) has announced the sampling of its new A10159 XBAW filter, designed for 5.9 GHz applications, meeting C-V2X and DSRC standards. Production is expected to ramp up in Q4 2023. The A10159 filter promises low insertion loss and high-power handling, facilitating long-range communication in automotive and wireless sectors. Key features include AEC-Q200 Grade 2 compliance, a compact form factor of 1.1 x 0.9 x 0.39 mm, and robust performance across various temperatures. Currently, Akoustis is boosting its production capacity to reach approximately 500 million units annually and has secured over 20 customer design wins for its XBAW filter solutions.
Akoustis Technologies (NASDAQ: AKTS) announced a new development order for Wi-Fi 6E/7 XBAW® filter solutions targeting the access point market. This order comes from a leading Asian RF front-end module maker, with qualified parts expected by mid-2024. Akoustis aims to leverage its existing designs and extensive product portfolio to support the customer's enhancement of their Wi-Fi offerings. The company reports strong demand for its Wi-Fi, 5G mobile, and infrastructure products, achieving multiple design wins and increasing production capacity to approximately 0.5 billion filters annually.
Akoustis Technologies, Inc. (NASDAQ: AKTS) has appointed Michelle L. Petock to its board of directors, expanding the board to eight members. Petock, with 25 years of experience in finance and law, will contribute to the Strategic Development and Audit Committees. Co-Chairman Jerry Neal praised her extensive skills as a significant asset. During the December 2022 quarter, Akoustis reported strong demand for its 5G mobile and Wi-Fi products, with advancements in production capacity at its New York facility expected to reach 0.5 billion filters annually.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced on March 8, 2023, that Founder and CEO Jeff Shealy will attend the 35th Annual Roth Conference in Laguna Nigel, CA, from March 12-14, 2023. Investors can schedule meetings with management through their Roth representative. The company continues to see strong demand for Wi-Fi and 5G products, including its patented XBAW filters and new RFMi resonator solutions. Akoustis is ramping up production capacity at its New York facility to meet increasing orders, targeting 0.5 billion filters annually. Over 20 design wins have been achieved for its XBAW filters, crucial for mobile communications.
Akoustis Technologies (NASDAQ: AKTS) reported a record revenue of $5.9 million for the fiscal quarter ending December 31, 2022, marking a 59% year-over-year increase. The company anticipates further growth, projecting a sequential revenue increase of 20%-40% in the March quarter, driven by strong demand for its XBAW filter products in various markets including 5G and Wi-Fi. With the recent acquisition of GDSI and efforts to expand manufacturing in New York, Akoustis aims to leverage the CHIPS and Science Act of 2022. The company reported a net loss of $11.2 million for the quarter, with an operating loss of $12.9 million.